Repligen (RGEN) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue was $154M, down 3.2% year-over-year, with first half revenue at $305M; order momentum improved, with Q2 orders pacing above revenues and a book-to-bill ratio above 1.0.

• Net income for Q2 was $3.3M, down from $20.1M in Q2 2023; adjusted net income was $19M, with adjusted EPS of $0.33 (vs. $0.53 prior year).

• Pharma, consumables, and new modalities showed strong sequential and year-over-year growth, while CDMO orders rebounded; China remained a significant headwind, with revenues expected to be $10M lower than prior guidance.

• CEO transition announced: Tony J. Hunt to step down as CEO effective September 1, 2024, transitioning to Executive Chair; Olivier Loeillot to become CEO.

• Pending acquisition of Tantti Laboratory Inc. announced to strengthen Proteins and Chromatography franchises, expected to close in Q4 2024.

Financial highlights

• Q2 2024 revenue was $154M, down 3% year-over-year; first half revenue was $305M, down 11% year-over-year but up 5% excluding COVID and protein headwinds.

• Q2 adjusted gross margin was 49.6%, down 60 bps year-over-year but up 100 bps sequentially; GAAP gross margin was 49.8%.

• Q2 adjusted operating income was $16M, down $14M year-over-year; Q2 adjusted operating margin was 10% (down 8 pts year-over-year, up 2 pts sequentially).

• Q2 adjusted EBITDA margin was 15%; Q2 adjusted net income was $19M.

• Cash and equivalents increased to $809M at June 30, 2024, up from $751M at year-end 2023.

Outlook and guidance

• FY 2024 revenue guidance narrowed to $620M–$635M, representing a (3%) to (1%) year-over-year change, with 2%–5% non-COVID growth expected.

• Adjusted EPS guidance for FY 2024 remains at $1.42–$1.49; GAAP EPS guidance is $0.17–$0.24.

• Adjusted gross margin guidance remains at 49%–50%; adjusted operating margin expected at 12%–13%; adjusted EBITDA margin at 17%–18%.

• Second-half 2024 revenue expected to be stronger, with non-COVID growth projected at 11% year-over-year.

• Adjusted effective tax rate for 2024 updated to 20%.